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The peroxisome proliferator-activated receptors (PPARs), which are ligand-inducible transcription factors expressed in a variety
of tissues, have been shown to perform key roles in lipid homeostasis. In physiological situations such as fasting and physical
exercise, one PPAR subtype, PPARδ, triggers a transcriptional program in skeletal muscle leading to a switch in fuel usage from
glucose/fatty acids to solely fatty acids, thereby drastically increasing its oxidative capacity. The metabolic action of PPARδ has
also been veriﬁed in humans. In addition, it has become clear that the action of PPARδ is not restricted to skeletal muscle. Indeed,
PPARδ has been shown to play a crucial role in whole-body lipid homeostasis as well as in insulin sensitivity, and it is active not
only in skeletal muscle (as an activator of fat burning) but also in the liver (where it can activate glycolysis/lipogenesis, with the
produced fat being oxidized in muscle) and in the adipose tissue (by incrementing lipolysis). The main aim of this review is to
highlight the central role for activated PPARδ in the reversal of any tendency toward the development of insulin resistance.
Copyright © 2008 Pieter de Lange et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The modern Western lifestyle is characterized by excessive
food intake and lack of physical exercise. This has led
to obesity caused by a disturbance of lipid homeostasis,
becoming one of the most prevalent and serious global
chronic disorders. In lean organisms, fatty acids derived
either from food or from hepatic lipogenesis are utilized
as energy substrates by the heart and skeletal muscles. A
strict physiological equilibrium between lipid availability
and lipid consumption needs to be maintained to prevent
development of both an impairment of insulin responsive-
ness and a metabolic dysfunction. In adult obesity and
obesity-associated metabolic disorders (which have strict
associations with type 2 diabetes, hypertension, and hyper-
lipidemia, and are often referred to as metabolic syndrome
[1]), a disturbance of lipid homeostasis causes excess fat
accumulation in various tissues (predominantly in adipose
tissues, but also in other insulin-responsive organs, such as
skeletal muscle and liver).
Skeletal muscle is quantitatively the largest organ in the
body, and it contributes 30–40% of the resting metabolic
rate in adults. It is a major site for the oxidation of
fatty acids and glucose (accounting for approximately 80%
of insulin-stimulated glucose uptake), and it exhibits a
remarkable ﬂexibility in its usage of fuel. One notable aspect
of skeletal muscle plasticity is the speciﬁcity of its structural,
biochemical, and functional adaptations to a given stimulus
[2]. In view of the above features, it is perhaps not surprising
that the predominant feature of type 2 diabetes is insulin
resistance in skeletal muscle [3, 4].
The peroxisome proliferator-activated receptors
(PPARs), which are ligand-inducible transcription factors
expressed in a variety of tissues, have been shown to
perform key roles in lipid homeostasis. In physiological
situations such as fasting [5] and physical exercise [6],2 PPAR Research
one PPAR subtype, PPARδ, triggers a transcriptional
program in skeletal muscle leading to a switch in fuel usage
from glucose/fatty acids to solely fatty acids, and thereby
drastically increasing this tissue’s oxidative capacity. In
addition, recent evidence has highlighted the possibility
that activating PPARδ in human subjects could increase
skeletal muscle’s oxidative capacity and so reverse metabolic
abnormalities [7]. In mouse models, PPARδ has been shown
to play a crucial role in whole-body lipid homeostasis as
well as in insulin sensitivity, and to be predominantly active
in skeletal muscle (as an activator of fat burning [8, 9]) but
also in the liver (where it can activate glycolysis/lipogenesis,
with the produced fat being oxidized in muscle [10]) and
in the adipose tissue (by incrementing lipolysis [11]).
Thus PPARδ activation provides a multiorgan “energy
substrate-switching” phenotype that triggers tissue-speciﬁc
transcriptional programs, and in which skeletal muscle plays
a crucial role by reducing fat content.
From the current data presented in the literature,
a central role for activated PPARδ can be deduced in
skeletal muscle, liver, and white adipose tissue (increased
fat oxidation in muscle, increased carbohydrate catabolism
and fat synthesis in the liver, and increased lipolysis in
white adipose tissue) in the reversal of any tendency
toward the development of insulin resistance. Following
a brief description of the structure, the mode of activa-
tion and the action of the PPARs, this review aims to
highlight the multiorgan energy switching role of PPARδ
and its ultimate impact on insulin resistance. Figure 1
represents an overview of the central role played by
PPARδ in the use of fatty acids as fuel by enhanc-
ing: (a) their oxidation in skeletal muscle (described in
Section 3), (b) their synthesis from glucose in the liver and
their subsequent release (described in Section 4), and (c)
their release from the white adipose tissue (described in
Section 5).
2. PPARS, NUCLEAR RECEPTORS ACTIVATED BY
FATTY ACIDS
PPARs are nuclear receptors that act as ligand-inducible
transcription factors. The three known isoforms PPAR α, β
(also termed δ),a n dγ display tissue-speciﬁc expressions
and possess diﬀerent gene-regulatory proﬁles. PPARγ is a
key regulator of adipose development and adipose insulin
sensitivity [12], whereas PPARα-regulated genes are involved
in hepatic lipid oxidation [13]. The PPARδ isoform, the
function of which has only recently been elucidated and
will be discussed in detail in this review, is predominantly
expressed in skeletal muscle (where it induces fatty acid
oxidation), but it is also expressed in brain, heart, liver,
adipose tissue, and small intestine [14, 15].
It is generally known that PPARs heterodimerize with
the retinoid X-receptor (RXR) and bind to a speciﬁc
DNA sequence, (a sequence termed peroxisome prolifera-
tors response element (PPRE), that is found in a variety
of genes involved in lipid and carbohydrate metabolism,
inﬂammation, and cell proliferation and diﬀerentiation) [16,
17]. However, alternative mechanisms exist. Recently, an
interplay has been reported between PPARδ and thyroid
hormone receptor β (TRβ) in the activation of the gene
encoding uncoupling protein 3 (UCP3) [18] in rat skeletal
muscle as well as in cotransfection experiments in rat L6
myoblasts containing a reporter construct driven by the rat
UCP3 promoter. Activation of UCP3 gene transcription in
vivo by thyroid hormone (T3) requires the presence of fatty
acids,whileintheabsenceoffattyacidsthistranscriptioncan
be restored by the PPARδ agonist L165,041 [18]. The UCP3
gene promoter has been shown to contain a noncanonical
thyroid hormone response element (TRE) termed TRE1
that is conserved from rodents to humans [18, 19], and
this response element is also recognized by PPARs [19].
Interestingly, fatty acid responsiveness after T3 treatment
was only observed in cells transfected with the rat UCP3
promoter, which suggests a species-speciﬁc regulation [18].
Dietary fatty acids and fatty acid derivatives are the natu-
ralligandsofPPARs,whichdisplaythegreatestpreferencefor
monounsaturated and polyunsaturated fatty acids (MUFAs
and PUFAs, resp.), as demonstrated by means of various
ligand-binding assays [20, 21]. The fact that each PPAR
activates a diﬀerent gene program, despite their overlapping
expressions,wouldseemtosuggestligand-speciﬁcityforeach
PPAR. Indeed, the structure of the ligand-binding pocket
diﬀers considerably among the various PPARs as revealed
by X-ray crystal-structure analysis [21, 22]. Nevertheless,
natural fatty acids can be ligands of all three PPAR isoforms.
It is well known that binding of the ligand promotes a
conformational change that is permissive for interactions
with tissue-speciﬁc coactivator proteins, allowing nucleo-
some remodelling and activation of the transcription of cell
type-speciﬁctargetgenes[21,23].Itis,therefore,conceivable
that a given fatty acid induces diﬀerent conformational
changes when binding to the ligand-binding pockets of
the various PPAR subtypes. Given that the transcriptional
activity induced by each PPAR subtype is cell type-speciﬁc
[24], the diﬀerent conformations induced following ligand
binding may determine the cell-speciﬁcity of the diﬀerent
PPARs (through heterodimerization with diﬀerent receptors
and binding to cell-type speciﬁc cofactors). However, further
research is needed to establish which natural ligands might
activate each PPAR in a given cellular context.
3. ROLE OF PPARδ IN SKELETAL MUSCLE:





10- and 50-fold higher levels than PPARα and PPARγ,r e s p . ;
[15, 25]) as well as its preferential expression in oxidative
rather than glycolytic myoﬁbers [9], has led to the suggestion
that this receptor isoform may be involved in promoting
the utilization of fatty acids as fuel. Indeed, treatment of
rat L6 cells with the highly speciﬁc PPARδ agonist GW0742
has been shown to increase fatty acid oxidation and induce
expression of several lipid regulatory genes [26]. In addition,Pieter de Lange et al. 3
treatment of C2C12 cells with GW0742 [27]o rw i t h
another the PPARδ-speciﬁc agonist (GW1516 [28]) induced
expressions of genes involved in lipid catabolism and energy
uncoupling in skeletal muscle cells [29]. However, although
an in vivo magnetic resonance spectroscopy (MRS) study of
rats treated with the latter agonist revealed increased lipid
metabolism, no change in mitochondrial energy coupling
wasdetectedeﬃciencydespiteanincreasedUCP3expression
[29]. Skeletal muscle has the capacity to adapt its structure
to metabolic changes, as indicated by changes in the myosin
typeandasubsequentshiftinthenumberandtypeofmuscle
ﬁbers. An increased demand for fat metabolism is reﬂected
by a shift in ﬁber-type away from the fast, glycolytic form
(type II) toward the slow-oxidative form (type I) [2]. PPARδ
has emerged as an important stimulus in the induction of
this ﬁber shift. Indeed, studies on transgenic mice harboring
a constitutively activated form of PPARδ (VP16-PPARδ)
have clearly shown an increase in skeletal muscle lipid
metabolism as well as the formation of type I ﬁbers [9]. Mice
overexpressing peroxisome proliferator-activated receptor γ
coactivator 1 α (PGC-1α), which activates PPARδ via a direct
protein-protein interaction [30], have been shown to possess
ah i ghc o n t e n to ftyp eIﬁ b e r s[ 31]. However, experiments on
mice overexpressing VP16-PPARδ have revealed that type I
ﬁber formation can be directly stimulated by PPARδ without
an induction of PGC-1α [9]. Nevertheless, in physiological
situations, an upregulation of PGC-1α is likely to be involved
in the early events leading to muscle-ﬁber shifts, since PGC-
1α is a coactivator of the PPARs. Indeed, PGC-1α-null
mice show clear muscle dysfunction [32], and evidence that
PPARδ induces an expression of PGC-1α has come from
treatment of mice with GW1516 [8]a sw e l la sf r o mas t u d y
in which skeletal muscle C2C12 myocytes transfected with
aP G C - 1 α promoter-driven reporter construct were treated
with the same ligand [33]. A wild-type PPARδ transgene
(speciﬁcally overexpressed in mouse skeletal muscle, but
not constitutively activated) has been shown to promote
a net increase in the number of ﬁbers with an oxidative
metabolic capability through an increase in ﬁber numbers
in soleus and tibialis anterior muscle, while in plantaris
muscle the increase was more closely related to a shift
from glycolytic to more oxidative ﬁbers [34]. Interestingly,
this nonactivated PPARδ transgene failed to induce the
formation of type I ﬁbers in skeletal muscle [34]. In this
case, despite its high expression, actual activation of the
transgene would depend on the presence of natural ligands,
such as fatty acids. As the fatty acid concentrations ﬂuctuate,
fatty regulation of PPARδ transcription is likely to be highly
regulated.
This raises the question as to whether, instead of
overexpression, increasing the availability of ligand (natural
or artiﬁcial) would induce fuel switching as well as ﬁber
switching toward type I ﬁbers. Indeed, a fuel-switching role
of PPARδ activation has been demonstrated by incubating
rat isolated skeletal muscle strips with the agonist GW1516
for 24 hours [35]. This led to an increased use of fatty acids
over glucose, as reﬂected by increased fatty acid oxidation
and reductions in glucose oxidation, glycogen synthesis, lac-
tate release, and glucose transport. Interestingly, this switch
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Figure 1: Central, fuel-switching mechanisms by which PPARδ
increases the use of fatty acids in skeletal muscle without provoking
insulin resistance. Dotted arrow: indirect eﬀect. For abbreviations,
t h er e a d e ri sr e f e r r e dt ot h et e x t .
was independent of insulin stimulation or ﬁber type [35].
The PPARδ agonist GW610742 also induced this fuel switch
andinadditiontriggeredageneticprogramtowardinitiation
of muscular atrophy without compromising mitochondrial
activity in rat skeletal muscle [36]. Furthermore, a somatic
gene transfer of PPARδ into adult rat ﬁbers has recently been
shown to lead to activation of fuel switching as well as to a
shift in the existing ﬁber proﬁle toward the “slow,” oxidative
phenotype, an eﬀect that caused the number of type I ﬁbers
in the extensor digitorum longus (EDL) muscle to be tripled
after 14 days [37]. From these experiments, it is clear that





Recent studies have revealed clear roles for PPARδ in the
regulationoflipidandglucosemetabolisminhumanskeletal
muscle [7, 38]. PPARδ stimulates the expression of genes
involved in (a) increasing of lipid oxidation (fatty acid
binding protein 3 (FABP3) and CPT1) and (b) reducing
carbohydrate oxidation (pyruvate dehydrogenase kinase 4
(PDK4)) in human skeletal muscle [38], as it does in
rodents [5, 8–10]. These in vitro human skeletal muscle
data with GW1516 support the long-known observation
that an increase in fatty acid oxidation reduces the glucose
utilizationofisolatedmusclereﬂectingthemutualinhibition
in the metabolism of substrates involved in the glucose-fatty
acid cycle [35, 36, 39]. Recent data from a clinical study
indicate that this situation holds true in human subjects. A
statistically signiﬁcant reduction in fasting insulin levels was
observed in a study performed on moderately obese men
given a dose of 10mg o.d. of GW1516 was given for 2 weeks4 PPAR Research
[7]. These subjects also showed decrease fasting plasma
nonesteriﬁedfattyacid(NEFA)concentrationsandincreased
expression of CPT1b in muscle. Interestingly, GW1516
treatmentslightlyreducedtheexpressionofPPARδ,showing
that overexpression of the receptor itself is not necessary for
the induction of PPARδ-mediated eﬀects, the resident levels
of the receptor protein being suﬃcient. In contrast, similar
treatment with a PPARα agonist (GW590735) did not result
in any change in plasma insulin levels, nor did it cause a
signiﬁcant increase in CPT1b mRNA [7].
3.3. PPARδ:aregulatoroffueluseinskeletalmuscle
underphysiologicalconditions
Since fasting promotes increased utilization of fatty acids,
fasting might also regulate PPARδ expression. However, the
initial reports appearing in the literature did not seem to
conﬁrm this. For instance, a 24-hour fasting period was
found not to upregulate PPARδ in rat skeletal muscle [40],
and our group even reported reduced levels of PPARδ (and
PPARα) in gastrocnemius muscle from 48-hour-fasted rats
[25]. Decreased expressions of PPARδ and PPARα upon 48
hours of fasting have recently been reported in humans,
too [41]. In contrast, in mice, skeletal muscle PPARδ levels
were found to be upregulated after a 24-hour fast [42]. One
explanation is that studying the responses to physiological
stimuli by making single time point measurements may give
misleading results, due to possible transient modiﬁcations.
Indeed, time course studies have shown that PPARδ actually
is upregulated in fasted rat skeletal muscle, but within
the ﬁrst 6 hours [43]. This upregulation of PPARδ (and
of PGC-1α) during fasting is, however, transient [43],
downregulation (after the initial upregulation at 6 hours
to around or below the control levels being evident at 48
hours). Data showing that rapid nuclear accumulations of
both PGC-1α and PPARδ upon food deprivation [43], and
their physical interaction within the nucleus [30], occur
concomitantly with increases in fatty acid levels and an
increase in the expression of myosin heavy chain Ib (MHC
Ib), underline the role of PPARδ as a key regulator of fatty
acid metabolism and muscle ﬁber switching (in concert with
its coactivator, PGC-1α).
Following the nuclear accumulation of PPARδ, its target
genes (such as carnitine palmitoyl transferase 1b (CPT1b),
mitochondrial thioesterase I (MTE I), and UCP3) are upreg-
ulated simultaneously, and so is the rate of mitochondrial
fatty acid oxidation [43]. In starved mice, the mRNA for a
member of the FOXO family, FKHR (forkhead homolog in
rhabdomyosarcoma), is upregulated rapidly and transiently
(starting within 6 hours, peaking at 12 hours, and decreasing
at24hours),andthisisfollowedbyanupregulationofFKHR
protein and a nuclear accumulation of nonphosphorylated
FKHR levels with a consequent upregulation of its target
gene pyruvate dehydrogenase kinase 4 (PDK4) [44]. In
mouse skeletal muscle, PDK4 has been shown to be a target
of PPARδ, since it is activated in vivo by GW1516 [8].
This kinase plays an important role in the switching from
glucose usage to fat usage since it phosphorylates the E1
component of the pyruvate dehydrogenase (PDH) complex,
thereby downregulating carbohydrate (CH) oxidation [45].
Similarly, in human skeletal muscle, PDK4 mRNA and
protein levels have been found to be elevated at both 24
hours and 48 hours of fasting, whereas at these time points
the FOXO1 mRNA/protein levels were unchanged [41].
However, it is possible that regulation of the mRNA/protein
levels of FOXO1 (a target of PGC-1α [46], which are
transientlyregulatedduringfastinginrats[40])isatransient
event preceding upregulation of PDK4 mRNA and protein
in humans, too. If so, such transient regulatory changes may
have been missed by measuring only at 24 hours and 48
hours of starvation in humans. At the 48-hour time point
of starvation, PPARδ mRNA levels in the human vastus
lateralismuscleweredecreased[41],aﬁndinginlinewiththe
decreased levels of PPARδ mRNA [25] and nuclear protein
[43] at this time point in fasting rat gastrocnemius muscle.
In the rat, this decline was preceded by a rapid rise in
the mRNA and protein levels of this transcription factor,
elevatedlevelsbeingdetectedat6hoursand12hoursoffood
deprivation [43]. Unfortunately, these time points were not
investigated in the human study [41]. Thus kinetic studies
in the fasting situation, in rodents as well as in humans,
have made it clear that the expression of PPARδ, and that
of its target genes, is tightly regulated. These results oﬀer an
explanation for the rapid structural and metabolic changes
favoring an increased use of lipids as fuel that occur in this
condition.
The reported kinetics of the PPARδ upregulation occur-
ring during the recovery period after exercise-imposed
energy stress in humans are in line with those seen in the
fasting rat; a single exhaustive bout of cycling increasing
PPARδ mRNA and protein expression within 3 hours after
completionoftheexercise[47,48].Regularphysicaltraining,
which elevates the levels of PPARδ and PGC-1α,l e a d s
to increases in both mitochondrial capacity and insulin
sensitivity [34, 49–51], eﬀects similar to those seen after
PPARδ activation. The observations made in exercise and
fasting experiments showing that PPARδ-expression kinetics
are rapid, and the changes almost immediate, are supported
by PPARδ acutely bringing about the fuel switching eﬀects
inpre-existing adult rat muscle ﬁbers (as demonstrated by
short-term agonist treatment [35, 36] and somatic PPARδ
gene transfer [36]). Recently, a direct role for PPARδ in the
suppression of glucose oxidation in fasting skeletal muscle
has been shown by Nahl´ e et al. [52]. First, the authors
demonstrated that deﬁciency of the fatty acid translocase
CD36 (mediating muscle fatty acid uptake during fasting,
[5]) blunts fasting induction of FOXO1 and PDK4 and
the associated suppression of glucose oxidation in mouse
skeletal muscle [52]. Next, they demonstrated that loss of
PPARδ abolishes the fasting induction of muscle FOXO1
and PDK4 in vivo [52]. As the authors identiﬁed several
PPRE sites in the FOXO1 promoter, these results suggest
that CD36-dependent activation of PPARδ results in the
trascriptional regulation of FOXO1 as well as PDK4 in fasted
mice.
Takentogether,thecontroloffuelusebyactivatedPPARδ
has emerged to be crucial for the rapid metabolic adaptation
of skeletal muscle to energy stress.Pieter de Lange et al. 5
4. ANTIGLYCEMIC ACTION OF PPARδ IN LIVER:
CONVERTING GLUCOSE INTO FAT
At ﬁrst glance, the above described PPARδ-mediated fuel
switching in skeletal muscle would be expected to give rise to
insulin resistance, since a preferential uptake and oxidation
of fatty acids (FFAs) over glucose (mediated by PPARδ stim-
ulation in skeletal muscle) would lead to an accumulation
of blood glucose, muscle being a major player in blood-
glucose homeostasis [1, 2]. However, as well as stimulating
skeletalmusclefattyacidoxidation,PPARδ playsasurprising
role in ameliorating hyperglycemia. It does this by increasing
hepatic glucose ﬂux through the pentose phosphate pathway
and by enhancing fatty acid synthesis, the fatty acids being
destined for oxidization in muscle [10]. Whereas PPARδ-
deprived mice are metabolically less active and glucose
intolerant, db/db mice treated with GW1516 show increased
levels of CPT in muscle [10] (similar eﬀects of this agonist
being reported in [8, 9]). This eﬀect on CPT is indicative of
increased fatty acid oxidation, so it was a surprising ﬁnding
that gene array analysis revealed increased expression of
gene clusters involved in fatty acid synthesis and the pentose
phosphate cycle in the liver [7], both pathways using glucose
or its metabolites as substrates. The authors [10]s u g g e s t e d
that PPARδ may increase glucose catabolism through these
processes, with the result that peripheral insulin sensitivity
may be improved [10]. Indeed, GW1516-treated db/db mice
showed an improved performance in the glucose tolerance
test, and also showed a tendency toward lowered fasting
serum insulin levels [10].
5. ROLE FOR PPARδ IN WHITE ADIPOSE TISSUE:
INCREASING LIPOLYSIS
Interestingly,adipocytehypertrophyinducedbyhigh-fatdiet
was accompanied by increased cannabinoid receptor type 1
(CB1R) expression and by a decrease in PPARδ expression in
adipose tissue [11]. Exercise attenuates adipocyte hypertro-
phy and normalizes expression of CB1R and PPARδ.F u n c -
tional cross-talk between CB1R and PPARδ is established by
RNA interference experiments in 3T3-L1 preadipocytes. For
example, selective silencing of PPARδ by RNA interference
signiﬁcantly increased CB1R and increased adipocyte diﬀer-
entiationandadenovirus-mediatedoverexpressionofPPARδ
reduced CB1R expression [11] .T h er o l eo fC B 1 Ri no b e s i t y
is well established [53]. Depletion of CB1R in knockout mice
is known (in animals fed a high-fat diet) to reduce obesity
through increased lipolysis [53].
The simultaneous regulation of skeletal muscle fatty acid
oxidationandadiposeproliferationbyPPARδ underlinesthe
powerful role this receptor may play in preventing weight
gain in physiological situations.
6. CONCLUSIONS
Recent evidence shows that the fuel-switching role of PPARδ
in skeletal muscle is conserved from rodents to humans.
This receptor is crucial for a modulation of skeletal muscle
ﬂexibility that directs this tissue toward the use of fatty acids
as fuel, an eﬀect with rapid kinetics. It is becoming increas-
ingly clear that even though the fat oxidation-inducing eﬀect
of PPARδ is exerted in skeletal muscle, this receptor also
activates transcriptional programs in other tissues (such as
adiposetissue,inwhichPPARδ directlyinhibits proliferation
and induces lipolysis), thereby channelling the fat consumed
in the diet directly to muscle for oxidation. In addition, in
an action that serves to prevent insulin resistance developing
as a consequence of a reduction of carbohydrate oxidation
in muscle, the liver is activated to form fat from glucose,
thereby both allowing skeletal muscle to oxidize more fat
and concomitantly lowering blood glucose levels. PPARδ is
emerging as a crucial nuclear receptor for the multiorgan
regulation of whole body fuel turnover, with skeletal muscle
as the central organ in the burning of fat and the consequent
prevention or reduction of obesity (see Figure 1). These
features make PPARδ a good candidate as a central target
for the future treatment of metabolic disturbances linked to
obesity and insulin resistance.
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